Research for markers of bone quality

Research for markers of bone quality - CLAST study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31945

Enrollment

100

Registered

2007-12-18

Start date

2008-08-04

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Postmenopausal women with a vertebral fracture and postmenopausal women without a vertebral fracture with high bone mineral density (T-score >-1 S.D.)

Exclusion criteria

Exclusion criteria: Medication influencing osteoclast function and formation (Bisphosphonates, Hormone Replacement Therapy, Strontium Ranelate, Teriparatide, Raloxifen)

Design outcomes

Primary

Measure	Time frame
Osteoclast formation will be studied by staining them with a Tartrate Resistant Acid Phosphatase staining. Bone resorption will be studied using a pit-assay to determine the surface and the number of resorption pits.	—

Secondary

Measure	Time frame
To study the expression of genetic markers of bone resorption and fractures, osteoclast will be seeded for RNA isolation. Furthermore, since osteoclast are derived from the hematopoietic line like lymfocytes, the PBMCs will be used to study the influence of lymfocytes and factors derived from lymfocytes on osteoclasts. Furhtermore blood will be collected as well to study biochemic and serum markers to be able to relate them to osteoporosis or other pathology.	—

Measure

Time frame

To study the expression of genetic markers of bone resorption and fractures, osteoclast will be seeded for RNA isolation. Furthermore, since osteoclast are derived from the hematopoietic line like lymfocytes, the PBMCs will be used to study the influence of lymfocytes and factors derived from lymfocytes on osteoclasts. Furhtermore blood will be collected as well to study biochemic and serum markers to be able to relate them to osteoporosis or other pathology.

—

Countries

Netherlands

Outcome results